AskGene Limited, a Camarillo, CA- and Nanjing, China-based clinical-stage biopharmaceutical company focusing on discovery and development of innovative biological drugs, closed a USD 20m Series A financing.
The round was led by Qiming Venture Partners and TF Capital.
Proceeds from the financing will be used to advance clinical development of its pipeline of innovative therapeutic candidates and development of SmartKine® cytokine prodrug platform.
Led by Jeff Lu, Chief Executive Officer, AskGene is advancing immunotherapies for cancers and autoimmune diseases. Through its SmartKine® platform technology and pipeline programs, the company aims to achieve its objective of modulating immune system at a disease site with selectivity and precision. Additional clinical stage programs include ASKB589 (an anti-CLDN 18.2 antibody in phase I/II) and ASKG712 (an anti-VEGF antibody-ANG2 antagonist peptide fusion molecule in phase I).
FinSMEs
09/05/2022